Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
  4. Changing the Mindset in the Management of Endometriosis: Hitting the Pause Button on Surgical Procedures and Expanding the Role of GnRH Antagonists

Changing the Mindset in the Management of Endometriosis: Hitting the Pause Button on Surgical Procedures and Expanding the Role of GnRH Antagonists

Pre- and Postoperative Use of GnRH Antagonists

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Related
Comments
  • Overview

    A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee Shulman, MD, FACOG, FACMG
    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL

    Dr. Shulman has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alliance Pharma, Amazon, Juniper Genomics, Mayne, Shield
    Speaker Fees: Daiichi Sankyo, Mayne, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
    Professor of Obstetrics and Gynecology
    The University of Chicago
    Chicago, IL

    Dr. Al-Hendy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, Myovant, ObsEvA, Pfizer,

    Sawsan As-Sanie, MD
    Associate Professor, Obstetrics and Gynecology
    Director of the Endometriosis Center
    University of Michigan
    Ann Arbor, MI

    Dr. As-Sanie has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, Gedeon Richter, Organon, Sumitomo
    Research: Sumitomo

    Linda Bradley, MD
    Professor of Obstetrics & Gynecology and Reproductive Medicine
    Cleveland Clinic
    Cleveland, OH

    Dr. Bradley has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Receives Royalties: Wolters Kluwer, UpToDate
    Medical Director: AAGL

    James A. Simon, MD, CCD, NCMP, IF, FACOG
    Clinical Professor, Obstetrics and Gynecology
    George Washington University
    Women’s Health & Research Consultants
    IntimMedicine Specialists
    Washington, DC

    Dr. Simon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Grant/research support: AbbVie, Inc., Bayer Healthcare LLC, Daré Bioscience, Ipsen, Mylan/Viatris Inc., Myovant Sciences, Sebela Pharmaceuticals Inc. 
    Consultant/advisory boards: Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, California Institute of Integral Studies (CIIS), Daré Bioscience, Femasys Inc., Khyria, Madorra Pty Ltd., Mayne Pharma, Inc., Pfizer Inc., Vella Bioscience Inc. 
    Speaker's bureaus: Ascend Therapeutics, Astellas Pharma, Inc., Mayne Pharma, Inc., Myovant Sciences, Inc., Pfizer Inc., Pharmavite LLC., Scynexis Inc. 
    Stockholder (direct purchase): Sermonix Pharmaceuticals 

    Melissa Simon, MD
    Vice Chair and Professor, Obstetrics and Gynecology
    Founding Director, Center for Health Equity Transformation
    Lurie Cancer Center
    Associate Director, Community Outreach & Engagement
    Northwestern University Feinberg School of Medicine
    Chicago, IL

    Dr. Simon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No relevant relationships to report

    Patient Advocate:
    Samantha Denäe
    Endometriosis Educator
    Atlanta, GA

    Samantha Denäe has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No Relevant relationships reported

    Casey Joe Hinds
    Patient Advocate & Community Influencer
    Atlanta, GA

    Casey Hinds has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    No Relevant relationships reported

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Brian McDonough has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the role of early diagnosis in improving both psychosocial and physical outcomes for patients with endometriosis
    • Incorporate patient-centric diagnostic and evaluation tools into clinical practice to better assess endometriosis and foster shared decision-making during its management
    • Create a practice environment that is patient-centric for all patients 
    • Identify the benefits and disadvantages of the GnRH antagonists in the management of endometriosis 
  • Target Audience

    This activity has been designed to meet the educational needs of gynecologists and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with endometriosis.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.75 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until August 9, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.75 contact hours/0.175 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-071-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from SMPA-Pfizer Alliance.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule9 Oct 2024